The device, called a biohybrid mesh harvester, consists of numerous tiny ribbons of lead zirconate titanate (PZT), a piezoelectric ceramic that generates an electrical charge when deformed, embedded in an open polymer mesh. When human cardiac cells are grown into the mesh, their contractions compress the PZT ribbons, producing electricity across multiple points in the tissue.
Unlike earlier piezoelectric harvesters, which are typically single devices attached to the surface of tissue, the new architecture distributes hundreds of miniature generators throughout the living structure. The researchers say this distributed design allows for closer mechanical coupling with cellular movements while maintaining the flexibility needed to accommodate biological motion.
“The beauty of this system is how noninvasive and powerful it is,” said Jun Yao, senior author of the study and associate professor at UMass Amherst’s Riccio College of Engineering. “Our bodies want to reject systems that come with bulk batteries, but when the device exists at the cellular level, you get vastly improved biocompatibility.”
The technology remains at an early stage, it has only been tested in laboratory-grown cardiac tissue, not in a living organism. Questions remain about long-term durability, electrical output, and the safety of PZT, which contains lead and would need to be isolated from surrounding tissue.
If successful, the approach could eventually power medical implants such as pacemakers, cardiac monitors, and neurostimulators, as well as wearable health devices. Roughly 120 million US adults, about 46% of the adult population, own wearable devices such as smartwatches and smart rings, according to the 2025 Rock Health Consumer Adoption Survey, all of which rely on batteries that need recharging or replacement.